First Chinese Patent for pSivida Limited
pSivida is currently in exploratory discussions with commercialisation partners for the Chinese market for its lead product BrachySil(tm) and is investigating the optimum regulatory process to launch this product in China. It is expected that pSivida would enter into a supply agreement with a local distributor responsible for obtaining regulatory approval, sales and marketing.
Chinese Patent Number ZL 99807447.0 provides protection for silicon implants comprising tissue compatible biodegradable silicon for drug delivery. This invention was based on the demonstration in model systems, that long term BioSilicon(tm) implants lack toxicology and degrade in the body in a controllable manner. It also claims the loading of BioSilicon(tm) implants of varying porosity and structure with different drugs.
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.